The Prospective Health Assessment of Cataract Patients' Ocular Surface (PHACO) study: the effect of dry eye

William B Trattler, Parag A Majmudar, Eric D Donnenfeld, Marguerite B McDonald, Karl G Stonecipher, Damien F Goldberg, William B Trattler, Parag A Majmudar, Eric D Donnenfeld, Marguerite B McDonald, Karl G Stonecipher, Damien F Goldberg

Abstract

Purpose: To determine the incidence and severity of dry eye as determined by the International Task Force (ITF) scale in patients being screened for cataract surgery.

Patients and methods: This was a prospective, multi-center, observational study of 136 patients, at least 55 years of age, who were scheduled to undergo cataract surgery. The primary outcome measure was the incidence of dry eye as evaluated by grade on the ITF scale and secondary outcome measures include tear break-up time (TBUT), ocular surface disease index score, corneal staining with fluorescein, conjunctival staining with lissamine green, and a patient questionnaire to evaluate symptoms of dry eye.

Results: Mean patient age was 70.7 years. A total of 73.5% of patients were Caucasian and 50% were female. Almost 60% had never complained of a foreign body sensation; only 13% complained of a foreign body sensation half or most of the time. The majority of patients (62.9%) had a TBUT ≤5 seconds, 77% of eyes had positive corneal staining and 50% of the eyes had positive central corneal staining. Eighteen percent had Schirmer's score with anesthesia ≤5 mm.

Conclusion: The incidence of dry eye in patients scheduled to undergo cataract surgery in a real-world setting is higher than anticipated.

Keywords: International Task Force scale; cataract surgery screening; dry eye; observational study.

Conflict of interest statement

Disclosure None of the authors have a financial interest in any product mentioned, but all are consultants to Allergan. In addition, EDD, MBM, KGS, and WBT are consultants to Shire. The authors report no other conflicts of interest in this paper.

References

    1. Cho YK, Kim MS. Dry eye after cataract surgery and associated intra-operative risk factors. Korean J Ophthalmol. 2009;23(2):65–73.
    1. Han KE, Yoon SC, Ahn JM, et al. Evaluation of dry eye and meibomian gland dysfunction after cataract surgery. Am J Ophthalmol. 2014;157(6):1144.e1–1150.e1.
    1. Yao K, Bao Y, Ye J, et al. Efficacy of 1% carboxymethylcellulose sodium for treating dry eye after phacoemulsification: results from a multicenter, open-label, randomized, controlled study. BMC Ophthalmol. 2015;15:28.
    1. Movahedan A, Djalilian AR. Cataract surgery in the face of ocular surface disease. Curr Opin Ophthalmol. 2012;23(1):68–72.
    1. Kasetsuwan N, Satitpitakul V, Changul T, Jariyakosol S. Incidence and pattern of dry eye after cataract surgery. PLoS One. 2013;8(11):e78657.
    1. Sullivan BD, Crews LA, Sönmez B, et al. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea. 2012;31(9):1000–1008.
    1. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21(4):221–232.
    1. Lee JH, Song IS, Kim KL, Yoon SY. Effectiveness and optical quality of topical 3.0% diquafosol versus 0.05% cyclosporine A in dry eye patients following cataract surgery. J Ophthalmol. 2016;2016:8150757.
    1. Kwon JW, Chung YW, Choi JA, La TY, Jee DH, Cho YK. Comparison of postoperative corneal changes between dry eye and non-dry eye in a murine cataract surgery model. Int J Ophthalmol. 2016;9(2):218–224.
    1. Yu Y, Hua H, Wu M, et al. Evaluation of dry eye after femtosecond laser-assisted cataract surgery. J Cataract Refract Surg. 2015;41(12):2614–2623.
    1. Balaram M, Dana MR. Phacoemulsification in patients after allogeneic bone marrow transplantation. Ophthalmology. 2001;108(9):1682–1687.
    1. Liu X, Gu YS, Xu YS. Changes of tear film and tear secretion after phacoemulsification in diabetic patients. J Zhejiang Univ Sci B. 2008;9(4):324–328.
    1. Oh T, Jung Y, Chang D, Kim J, Kim H. Changes in the tear film and ocular surface after cataract surgery. Jpn J Ophthalmol. 2012;56(2):113–118.
    1. Li XM, Zhao X, Hu LZ, Wang W. Clinical observation of dry eye in patients before and after cataract surgery. Zhonghua Yan Ke Za Zhi. 2007;43(1):10–13. German.
    1. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf. 2007;5(2):163–178.
    1. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405–412.
    1. Sánchez MA, Arriola-Villalobos P, Torralbo-Jiménez P, et al. The effect of preservative-free HP-Guar on dry eye after phacoemulsification: a flow cytometric study. Eye (Lond) 2010;24(8):1331–1337.
    1. Sandoval HP, Fernández de Castro LE, Vroman DT, Solomon KD. A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical infl ammation following cataract and refractive surgery. Clin Ophthalmol. 2007;1(4):367–371.
    1. Devendra J, Singh S. Effect of Oral Lactoferrin on Cataract Surgery Induced Dry Eye: A Randomised Controlled Trial. J Clin Diagn Res. 2015;9(10):NC06–NC09.
    1. Pan Q, Angelina A, Zambrano A, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2013;(8):CD009327.
    1. Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol. 2013;27(3):167–171.
    1. Galor A, Zheng DD, Arheart KL, et al. Dry eye medication use and expenditures: data from the medical expenditure panel survey 2001 to 2006. Cornea. 2012;31(12):1403–1407.
    1. Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207–215.
    1. Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–483.
    1. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25(8):900–907.
    1. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21(4):221–232.
    1. Savini G, Prabhawasat P, Kojima T, Grueterich M, Espana E, Goto E. The challenge of dry eye diagnosis. Clin Ophthalmol. 2008;2(1):31–55.
    1. Dougherty BE, Nichols JJ, Nichols KK. Rasch analysis of the Ocular Surface Disease Index (OSDI) Invest Ophthalmol Vis Sci. 2011;52(12):8630–8635.
    1. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615–621.
    1. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf. 2007;5(2):93–107. No authors listed.
    1. Asbell PA, Spiegel S. Ophthalmologist perceptions regarding treatment of moderate-to-severe dry eye: results of a physician survey. Eye Contact Lens. 2010;36(1):33–38.
    1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf. 2007;5(2):75–92. No authors listed.
    1. Imbert Y, Foulks GN, Brennan MD, et al. MUC1 and estrogen receptor alpha gene polymorphisms in dry eye patients. Exp Eye Res. 2009;88(3):334–338.
    1. Jackson WB. Management of dysfunctional tear syndrome: a Canadian consensus. Can J Ophthalmol. 2009;44(4):385–394.
    1. Khaireddin R, Schmidt KG. Comparative investigation of treatments for evaporative dry eye. Klin Monbl Augenheilkd. 2010;227(2):128–134. Chinese.
    1. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337–342.
    1. Pflugfelder SC. Dry eye. Focal Points. 2006;25(5):1–15.
    1. Pflugfelder SC, de Paiva CS, Tong L, Luo L, Stern ME, Li D. Stress-activated protein kinase signaling pathways in dry eye and ocular surface disease. Ocul Surf. 2005;3(4 Suppl):S154–S157.
    1. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002;966:211–222.
    1. Lee SY, Petznick A, Tong L. Associations of systemic diseases, smoking and contact lens wear with severity of dry eye. Ophthalmic Physiol Opt. 2012;32(6):518–526.
    1. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009;127(6):763–768.
    1. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318–326.
    1. Yazdani C, McLaughlin T, Smeeding JE, Walt J. Prevalence of treated dry eye disease in a managed care population. Clin Ther. 2001;23(10):1672–1682.
    1. Chalmers RL, Begley CG, Edrington T, et al. The agreement between self-assessment and clinician assessment of dry eye severity. Cornea. 2005;24(7):804–810.
    1. Sullivan BD, Crews LA, Messmer EM, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol. 2014;92(2):161–166.
    1. Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203–3209.
    1. Koh S, Maeda N, Hirohara Y, et al. Serial measurements of higher-order aberrations after blinking in patients with dry eye. Invest Ophthalmol Vis Sci. 2008;49(1):133–138.
    1. Montés-Micó R, Alió JL, Charman WN. Postblink changes in the ocular modulation transfer function measured by a double-pass method. Invest Ophthalmol Vis Sci. 2005;46(12):4468–4473.
    1. Puell MC, Benítez-del-Castillo JM, Martínez-de-la-Casa J, et al. Contrast sensitivity and disability glare in patients with dry eye. Acta Ophthalmol Scand. 2006;84(4):527–531.
    1. Rolando M, Iester M, Macri A, Calabria G. Low spatial-contrast sensitivity in dry eyes. Cornea. 1998;17(4):376–379.
    1. Tutt R, Bradley A, Begley C, Thibos LN. Optical and visual impact of tear break-up in human eyes. Invest Ophthalmol Vis Sci. 2000;41(13):4117–4123.
    1. Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998;17(1):38–56.
    1. Cohen KL. Sterile comeal perforation after cataract surgery in Sjogren’s syndrome. Br J Ophthalmol. 1982;66(3):179–182.
    1. Li XM, Hu L, Hu J, Wang W. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007;26(9 Suppl 1):S16–S20.
    1. Ring L, Okoro M. Handbook of Ophthalmic Nursing Standards & Procedures. Keswick, UK: M & K Update Ltd; 2012.
    1. American Academy of Ophthalmology Cataract and Anterior Segment Panel . The Cataract in the Adult Eye Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology; 2016.
    1. Abelson MB, Ousler GW, 3rd, Nally LA, Welch D, Krenzer K. Alternative reference values for tear film break up time in normal and dry eye populations. Adv Exp Med Biol. 2002;506(Pt B):1121–1125.
    1. Wong J, Lan W, Ong LM, Tong L. Non-hormonal systemic medications and dry eye. Ocul Surf. 2011;9(4):212–226.
    1. Mah FS, O’Brien T, Kim T, Torkildsen G. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr Med Res Opin. 2008;24(2):441–447.
    1. Ousler GW, 3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther. 2007;29(4):611–616.
    1. Sekeroglu MA, Hekimoglu E, Tasci Y, Dolen I, Arslan U. Ocular surface changes following oral anticholinergic use for overactive bladder. Cutan Ocul Toxicol. 2016;35(3):218–221.
    1. Ozen Tunay Z, Ozdemir O, Ergintürk Acar D, Cavkaytar S, Ersoy E. Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence. Int Urogynecol J. 2016;27(6):919–922.
    1. Acan D, Kurtgoz P. Influence of selective serotonin reuptake inhibitors on ocular surface. Clin Exp Optom. 2017;100(1):83–86.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner